Van Wyk, J., Ajana, F., Bisshop, F., De Wit, S., Osiyemi, Y., Portilla, J., Routy, J., Wyen, C., Ait-Khaled, M., Nascimento, M., Pappa, K., Wang, R., Wright, J., Tenorio, A., Wynne, B., Aboud, M., Gartland, M., Smith, K., & El-Bahy, Y. (2020). switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study). Journal of infection and public health, 13(2), 349–. http://access.bl.uk/ark:/81055/vdc_100099964386.0x000015